---
schema_version: "secwatch.filing_event.v1"
accession: "0001372514-23-000051"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2023-03-23T23:59:59+00:00"
generated_at: "2026-06-17T17:52:23.298096+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kiora Pharmaceuticals reports FY2022 net loss of $13.6M; clinical milestones on track for 2023

## Summary
- Net loss of $13.6M for FY2022, compared to $13.8M in FY2021; Q4 net loss $2.5M.
- Cash and equivalents $6.0M at Dec 31, 2022, plus $1.4M in R&D tax receivables.
- KIO-301 Phase 1b ABACUS trial enrollment ongoing; initial results at ARVO April 2023, topline by year-end.
- KIO-201 Phase 2 PCED study topline results at ARVO; mean defect size reduction 90% (p<0.003).
- KIO-101 Phase 2 trial initiation planned for Q2 2023.

## SEC filing metadata
- accession: 0001372514-23-000051
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2023-03-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000137251423000051/0001372514-23-000051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000137251423000051/kprx-20230323.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001372514-23-000051
- JSON: https://secwatch.observer/filing/0001372514-23-000051.json
- Plain text: https://secwatch.observer/filing/0001372514-23-000051.txt

## Key facts
- Earnings Releases
  KIORA PHARMACEUTICALS INC reported financial results for the fiscal year and fourth quarter ended December 31, 2022.
  - Period: the fiscal year and fourth quarter ended December 31, 2022
  - Result: reported results
  source text: On March 23, 2023, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the fiscal year and fourth quarter ended December 31, 2022 and an update on clinical development progress.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372514/000137251423000051/0001372514-23-000051-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.